A New Titan in Weight Loss? CagriSema Delivers Stunning 22.7% Reduction
- A new drug, CagriSema, resulted in an average weight loss of 22.7% in a landmark trial published in the New England Journal of Medicine.
- Half of participants with obesity no longer met the clinical criteria for the condition after treatment.
- The dual-action drug combines the active ingredient in Ozempic with a second hormone-mimicking molecule.
The battle against obesity has a powerful new contender. In a stunning development, results from the landmark REDEFINE 1 trial show that Novo Nordisk’s investigational drug, CagriSema, helped adults shed an average of 22.7% of their body weight over 68 weeks6, 8.
This isn't just a number on a scale. The results were so profound that half of the participants who began the trial with obesity saw their BMI drop below the clinical threshold for the disease by the end of treatment. The drug achieves this by uniquely combining two molecules: semaglutide, the powerhouse behind Ozempic and Wegovy, and cagrilintide, a compound that mimics a different hormone to further reduce hunger and increase fullness3, 4, 5.
While facing off against formidable rivals like Eli Lilly's Zepbound, CagriSema demonstrated a well-tolerated safety profile. Side effects were primarily mild-to-moderate gastrointestinal issues, but discontinuation rates due to these events were remarkably low, a promising sign for real-world use4, 7. With further trials already underway to explore its long-term potential, CagriSema is poised to reshape the future of weight management8.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.